Sandramycin is primarily used in cancer research due to its antitumor properties. It functions as a DNA-binding agent, specifically interacting with the minor groove of DNA, which disrupts DNA replication and transcription in tumor cells. This mechanism makes it a potential candidate for the development of chemotherapeutic agents, particularly for targeting certain types of solid tumors. Its selective toxicity toward cancer cells is under investigation to improve efficacy and reduce side effects in future oncology treatments.